KY-ADTRAN
7.3.2024 14:31:27 CET | Business Wire | Press release
Adtran today announced that South Central Rural Telecommunications Cooperative (SCRTC) is using its ALM in-service fiber monitoring solution to continuously probe its fiber network for faults and degradations. The comprehensive assurance platform empowers SCRTC to locate and resolve issues before they impact services for its customers across South Central Kentucky. With no need to engage in time-consuming manual fault isolation, SCRTC can leverage its maintenance resources more effectively to improve service delivery for its subscribers. To enhance scalability, SCRTC has implemented Adtran’s ALM 96-port expansion unit at three of its hub sites. This enables efficient monitoring of up to 110 fiber links from a single hub location, significantly enhancing SCRTC’s capability to proactively detect and address faults.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240307876673/en/
SCRTC is using Adtran’s fiber monitoring solution to reduce network downtime and cut operational costs. (Photo: Business Wire)
“The moment we plugged ALM into our infrastructure, it notified us of an issue affecting one of our protected routes. We’d been told to expect a quick return on our investment, but to get an immediate demonstration of what it could do for us was a surprise,” said Lonnie Meredith, network manager at SCRTC. “The ALM’s ability to detect, identify and locate fiber faults in real time has had a profound impact on our operations, minimizing network downtime and cutting operational costs. It only becomes clear just how essential the Adtran ALM is once it’s operational in your network. For our subscribers, it means receiving high-speed broadband with unbeatable reliability. And for us, it translates into daily operations that are more efficient and more cost-effective. It’s a tool you can’t afford to be without.”
SCRTC is using the 16-port variant of Adtran’s ALM to continuously monitor its core fiber network and high-traffic routes alongside the 96-port extender at three hub sites. A key component of SCRTC’s network management system is Adtran’s GIS-based tracking solution, Ensemble Fiber Director. This works with ALM to precisely track the location of issues and ensure optimized oversight of SCRTC’s full optical infrastructure. The system acts like a radar that continuously scans fiber optic cables to pinpoint the location of issues such as attenuation, water damage and breaks. By identifying problems early and enabling maintenance teams to immediately track them down, ALM also helps reduce SCRTC’s operational and capital expenditures. What’s more, its fanless operation and low power consumption further contribute to network efficiency and cost-effectiveness.
“When a service outage occurs, subscribers expect rapid resolution. That’s because broadband has become such an essential utility. Businesses, people working from home and families who regularly access entertainment streaming demand consistent, always-on connectivity. That’s why service providers like SCRTC are seeking solutions that take network resiliency to the next level,” commented John Scherzinger, GM of Americas sales at Adtran. “It’s often not until our customers experience the benefits of ALM’s proactive monitoring firsthand that they fully appreciate its critical role in operations. The SCRTC team is now well aware of the advantages it brings in minimizing efforts, bolstering network resilience and ensuring customer satisfaction.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240307876673/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
